v3 Template
H

Hoth Therapeutics, Inc.

Biopharmaceuticals / Healthcare New York, USA ~150 employees
Founded
--
Employees (Est.)
~150
10 leaders known
Total Funding
$14.2M
Funding Rounds
2
Last Funding
2024-03-27

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a biopharmaceutical company focused on developing innovative, impactful, and ground-breaking treatments with the goal of improving patient quality of life. They act as a catalyst in early-stage pharmaceutical research and development, advancing promising drugs from bench to pre-clinical and clinical testing.

Products & Services

Oncology Treatments:Therapeutics focused on addressing unmet needs in oncology.
Neurology Treatments:Innovative solutions targeting neurological conditions.
Inflammatory Treatments:Therapies aimed at treating inflammatory disorders.
Devices:Development of medical devices as part of their therapeutic offerings.
Pipeline (HT-001 and others):A range of drug candidates in development, including HT-001 for various skin-related conditions.

Specialties

Early-stage pharmaceutical research and development Oncology therapeutics Neurology therapeutics Inflammatory disorder treatments Dermatology treatments Medical devices Artificial Intelligence in drug development

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Warrant Exercise
T: -
FT: Warrant Exercise
A: 4200000
MR: -
FA: 4.2 million
FAN: 4200000
D: 2024-03-27
FD: 2024-03-27
-
2 RT: Private Placement
T: -
FT: Private Placement
A: 10000000
MR: -
FA: $10 million
FAN: 10000000
D: 2023-01-03
FD: 2023-01-03
-
Warrant Exercise Latest
2024-03-27
$4.2M
Private Placement 2023-01-03
$10.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Robb Knie

Founder, President & Chief Executive Officer

M

Mario Lacouture, M.D.

Attending Physician and Director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center, and Professor in the Department of Dermatology at Weill Cornell Medicine

W

William Weglicki, M.D.

M.D.

G

Glenn Cruse, Ph.D.

Assistant Professor of Immunology

A

Adam Friedman, M.D., F.A.A.D.

Professor and Interim Chair of Dermatology

C

Carla Yuede, Ph.D.

Associate Professor in the Psychiatry Department

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Hoth Therapeutics, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceuticals / Healthcare
Company Size
~150 employees (est.)
Locations
New York, USA
New York

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro